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Objectives: To determine the cost-effectiveness of mechanical thrombectomy, 
compared with standard treatment, from the perspective of the UK NHS and 
PSS. MethOds: We undertook a cost-effectiveness analysis alongside the Pragmatic 
Ischaemic Stroke Thrombectomy Evaluation (PISTE) trial. In addition, a decision-ana-
lytic model was developed to estimate the long-term cost-effectiveness of thrombec-
tomy using all available trial evidence. Meta-analysis was used to estimate the clinical 
effectiveness; resource use and costs were sourced from the PISTE study and the 
broader literature. Value of implementation analysis was used to estimate the poten-
tial value of implementing this treatment into routine clinical practice within the UK 
NHS. As health budget responsibility is devolved within the UK, we plan to estimate 
the five-year budget impact of introducing mechanical thrombectomy into routine 
practice within the devolved NHS in Scotland. Results: Compared with standard 
treatment, thrombectomy was not shown to be cost-effective within-trial/90-day 
period. However, the reverse was observed with the long-term model (ICER £3,857 
per QALY gained). We estimate that 42,525 patients are potentially eligible to receive 
this treatment in the UK over a five year period. The net monetary benefit (health 
benefit in monetary terms) is £13,704 per patient. Assuming a five-year time horizon 
and full implementation, the value of implementation was £542 million. We estimate 
the “break-even” value of implementation activity point at approximately 26% imple-
mentation. cOnclusiOns: Based on a lifetime horizon, mechanical thrombectomy 
is cost-effective compared with standard care. If implementation is greater than 26%, 
the value of implementation is greater than the cost of implementation.
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Objectives: VTE prophylaxis implementation remains to be a challenge at KFSH 
with deterrent patient risk and death. The purpose of this study is to measure 
the degree of physician compliance to KFSH 2013 VTE prophylaxis protocol and to 
identify the percentage of patients at risk of VTE. MethOds: 103 patients admitted 
to various medical wards were reviewed of which 69 were included in our study. 
Their risk was measured using the risk assessment sheet in accordance to KFSH 
VTE prophylaxis protocol. Physicians’ compliance was assessed on their degree of 
compliance to KFSH 2013 VTE prophylaxis policy. Results: The overall compli-
ance rate with 2013 VTE prophylaxis among physicians was 1.4% in the 69 hospital 
admissions that were reviewed. The majority of our patients 56.5% received prophy-
laxis but not in accordance to policy. 41.7% of our patients had highest risk of VTE 
(> 5) according to their calculated risk. The highest risk 66.7% was observed in the 
Intensive Care Unit. cOnclusiOns: There is no adherence to VTE protocol among 
KFSH physicians which stresses the importance of awareness of VTE implications to 
patient well-being across KFSH medical staff. Patient risk of VTE is high and proper 
implementation is a must to reduce overall risk.
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Objectives: Several outcome-based agreements (OBA) have been signed in the 
past years with health plans in the Unites States for the reimbursement of the 
PCSK9 inhibitor evolocumab. We developed a model to determine what factors may 
impact the outcome measured under these OBAs in patients with athereosclerotic 
cardiovascular disease. MethOds: A Bayesian model was built in HOPE (Health 
Outcomes Performance Estimator), a tool that predicts drug outcomes under differ-
ent real world scenarios. Assumptions on efficacy of evolocumab versus placebo in 
terms of hazard ratio to time to first cardiovascular event, defined as cardiovascular 
death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary 
revascularization, came from a phase 3 randomised clinical trial (RCT) . Two virtual 
cohorts of 10,000 patients: one approximating the health plan population, one with 
characteristics as in the RCT, were created with different distributions of baseline 
age, weight, smoking status, LDL and HDL cholesterol levels, type of atherosclero-
sis, use of cardiovascular medications,and other factors including adherence. The 
impact of factors on baseline risk was extracted from the literature. To account for 
variability in inputs, we performed 1,000 simulations of cardiovascular events in 
each of the virtual cohorts. Results: The model estimates provided a good fit to 
time to cardiovascular event reported in the RCT. The estimated event rate 6 months 
after drug initiation in the health plan population was predicted to be higher than 
in the Phase 3 trial on average, with more variability due to higher variability in drug 
use and population characteristics. cOnclusiOns: We investigated how outcomes 
chosen to define the OBA terms on evolocumab could be affected in the population 
of health plan subscribers. Additional variability in population factors impacted the 
event rates which may in turn impact the financial results of the OBA, depending on 
the financial terms that were used.
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Objectives: This study aimed to describe real-world patterns of statin use in 
England. MethOds: Patients in the Clinical Practice Research Datalink linked 
treatment. The median time to first injection was 11 months post-stroke. The rate of 
treatment was different between age groups, with 31% of 40-59 year olds (+/- 1.1%) 
treated, compared to 11% of 70-79 year olds (+/- 0.8%; ). For patients with follow-up 
post-treatment of ≥ 2 years, only 9.5% were treated with ≥ 3 injections per year, and 
29% received only one injection. For patients with ≥ 2 injections, the mean time 
between 2 injections was 198 days (standard deviation: 171 days). cOnclusiOns: 
This analysis shows that only 1.6% of post-stroke patients were treated with BoNT. 
Given the impact of spasticity on the quality of life of patients, it is important that 
additional work is performed to identify which of the patient care pathways or 
clinical decisions defined a patients’ care and the therapeutic interventions used.
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Objectives: The objective of this study is to estimate the disease burden of Heart 
Failure (HF) in Portugal for 2014. MethOds: The HF burden was measured in 
Disability Adjusted Life Years (DALY) resulting from the sum of Years Lost due to 
Disability (YLD) and Years of Life Lost (YLL) due to premature death. YLL were esti-
mated based on the mortality rates reported by the European Detailed Mortality 
Database. For YLD, the three disability weights (mild moderate and severe) presented 
by the Global Burden of Disease Study (2015) were considered. Patients in the first 
class of the New York Heart Association (NYHA) Functional Classification, where 
considered to have no disability associated to HF. The average total disease duration 
by age group and the overall incidence were estimated using the software DisMod 
II, calibrated with the prevalence of NYHA class II-IV, relative risk of mortality and a 
remission rate of zero. Prevalence was estimated using the microdata of a previously 
conducted national community-based epidemiological survey while relative risk 
of mortality came from the international literature. It was assumed that incidence 
by severity class followed the same pattern as prevalence and that duration was 
independent from severity. Results: In 2014, HF incident cases in NYHA class II-IV 
were estimated to be 38,960 (394.74/100,000 inhabitants). The deaths for HF patients 
amounted to 4,688, 4.7% of overall deaths, with women being responsible for 66.7% 
of HF mortality. Overall, DALY totaled 21,162, with 53.8% due to YLL and 46.2% due 
to YLD. Women contributed to most of the overall disease burden in terms of DALY 
(57.0%) with YLL and YLD estimated at 6.944 and 5.118, respectively. cOnclusiOns: 
Heart Failure is an important cause of disease burden in Portugal. Heart Failure 
should be an important target for health policy interventions.
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Objectives: Hypertension medication and control are understudied among the 
elderly in middle-income countries, particularly as contextualized within social and 
community factors. MethOds: We used 2012 International Mobility in Aging Study 
data of community-dwelling adults 65-74 years across three study sites (Tirana, 
Albania n= 394; Natal, Brazil n= 402; Manizales, Colombia n= 407; N= 1,203). The study 
framework was the socioecological model, positing that individual-level health out-
comes are influenced by interpersonal (e.g., family, friends), organizational (e.g., 
health system), community (e.g., neighborhood safety), and policy levels. Logistic 
regression models identified factors associated with uncontrolled (vs. controlled) 
hypertension among those with diagnosed hypertension. Of particular interest was 
the role of antihypertensive medication contextualized within other factors speci-
fied by the socioecological model. Results: Among those with diagnosed hyperten-
sion, control was: Albania: 33%; Brazil: 30%; Colombia: 51%. At all sites, those not in 
control were less likely to have hypertension medications in their homes than those 
in control, but this difference only differed significantly in Brazil and Columbia. 
A high proportion of those not in control (> 80%) had antihypertensive medica-
tions at all sites. In final models, distinct factors from the socioecological model 
were strongly associated with uncontrolled hypertension across sites: Perceived 
income insufficiency (OR:3.23;95% CI:1.79-5.82) in Tirana; hypertension medication 
(OR:0.38;95%CI:0.16-0.88) and religious participation (OR:0.36;95% CI:0.13-0.97) in 
Colombia; and hypertensive medication (OR:0.38;95%CI:0.16-0.88) and strolling 
shops and stores (OR:0.44;95%CI:0.21-0.94) in Brazil. No behavioral variables (e.g. 
smoking, exercise, alcohol) were associated with control once organizational and 
community factors were considered. cOnclusiOns: In two of three middle-income 
study sites, all with low hypertension control, antihypertensive medication in the 
participants’ homes was significantly associated with a lower likelihood of uncon-
trolled hypertension. However, hypertension medication use was high across both 
controlled and uncontrolled hypertension. Contextualizing medication use within 
other socioecological factors is important to understand key predictors of hyperten-
sion control generally as well as variation across communities.
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